← Back to all trials
Completed
NCT07924176
Robot-Assisted Bronchoscopy for Lung Lesion Biopsy and Ablation
Conditions: Pulmonary Lesions
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: NA
Enrollment: 85
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Location: Shanghai Pulmonary Hospital Shanghai
Summary
This study evaluates whether robot-assisted bronchoscopy can be used successfully and safely to obtain tissue samples and perform local treatment of lung lesions at Shanghai Pulmonary Hospital, China. Lung lesions are abnormal areas seen on lung scans. Bronchoscopy uses a thin, flexible tube passed through the airways to reach these areas. A biopsy collects tissue to help establish a diagnosis. Ablation is a local treatment intended to destroy targeted abnormal tissue.
The prospective part of the study has three stages: biopsy, an initial evaluation of ablation, and biopsy followed by ablation during the same anesthesia session. Adults enter the appropriate group according to their clinical needs and suitability for the procedure, rather than by random assignment. The need for ablation is determined before the procedure. Imaging is used to confirm the positions of the lesion and instruments, and treatment may be adjusted or stopped if safety conditions are not met.
An exploratory comparison uses existing medical records of patients who underwent biopsy and ablation through the chest wall in separate procedures. Researchers compare this staged approach with biopsy and ablation performed through the airways in one session to explore differences in treatment completion time, time spent in hospital, and procedure duration.
The main outcome for the pathway comparison is the number of days from the first hospital admission to completion of the last planned ablation procedure. Other assessments include whether biopsy provides a diagnosis, whether planned ablation is completed, changes on follow-up scans, and procedure-related complications. After ablation, participants undergo computed tomography (CT) scans at 1 and 6 months, with an additional imaging assessment at either 9 or 12 months.
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years;
* CT-defined pulmonary lesions requiring tissue sampling or local ablation;
* Suitability for the intended robotic bronchoscopic procedure, with acceptable procedural and anaesthetic risk;
* Voluntary participation and written informed consent.
Exclusion Criteria:
* Inability to tolerate the intended procedure or required anaesthesia;
* Unacceptable bleeding risk;
* Absence of a safe procedural route or a lesion unsuitable for the intended procedure;
* Refusal to participate.
Source: ClinicalTrials.gov (NCT07924176). StuddyBuddy aggregates publicly available trial information.